FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* ROBIN HOWARD W							2. Issuer Name and Ticker or Trading Symbol NEKTAR THERAPEUTICS [NKTR]								of Reporting cable) or	' I		
(Last) (First) (Middle) C/O NEKTAR THERAPEUTICS 455 MISSION BAY BOULEVARD SOUTH						3. Date of Earliest Transaction (Month/Day/Year) 08/13/2015								X Officer (give title below) Other (specify below) President & CEO				specify
(Street) SAN FRANCISCO CA 94158 (City) (State) (Zip)					4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								i. Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Tak	le I - No	n-Deri	vativ	e Se	curit	ies Ac	quired,	Dis	sposed o	f, or Bei	neficial	y Owned				
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day					action	2/ Ex	A. Deemed Recution Date, any Ionth/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4		l (A) or	5. Amou Securiti Benefic Owned	int of es ially Following	Form (D) o	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)
Common Stock ⁽¹⁾ 08/13/2						015			M		58,333	A	\$6.98	68	,333		D	
Common Stock ⁽¹⁾ 08/13/2						015			S		58,333	D	\$10.89	10,000			D	
Common Stock														4	10		1 1	by spouse
		-	Table II -								osed of, convertil			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,	4. Transaction Code (Instr. 8)		ı of		6. Date Exercis Expiration Date (Month/Day/Ye		e	7. Title and of Securiti Underlying Derivative (Instr. 3 an	es g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares					
Stock Option ⁽¹⁾	\$6.98	08/13/2015			M			58,333	12/21/20	11	12/20/2015	Common	58,333	\$0.00	583,33	33	D	

Explanation of Responses:

- 1. This transaction was made pursuant to a Rule 10b5-1 trading plan for stock options scheduled to expire in 2015 as described in the Current Report on Form 8-K filed by Nektar Therapeutics on July 16, 2015.
- 2. This transaction was executed in multiple trades at prices ranging from \$10.40 to \$11.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

Remarks:

Gilbert M. Labrucherie, Jr., Attorney-in-Fact

08/17/2015

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.